Alternatives to Medincell
Medincell is a Biotechnology tool: a pharmaceutical company focused on developing long-acting injectable medicines. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to Medincell
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- JUJuno Therapeutics66BiotechnologySeattle, United States$316.7M
Biotechnology company focused on developing cancer immunotherapies.
- Website
Kite Pharma66BiotechnologySanta Monica, United States$421.2MBiotechnology company developing and commercializing cell therapies for cancer treatment.
- Website
CRISPR Therapeutics64BiotechnologyZug, Switzerland$547.0MBiotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Seaport Therapeutics62BiotechnologyCambridge, USA$340.0MDeveloping novel therapeutics to restore gut lymphatic function.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Supernus Pharmaceuticals60BiotechnologyRockville, United States$17.5MBiopharmaceutical company developing and commercializing CNS disease treatments.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- CRCreate Medicines60BiotechnologyCambridge, USA$122.0M
Developing in vivo immunotherapies for autoimmune diseases and cancer.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Compass Pathways57BiotechnologyLondon, United Kingdom$294.0MAccelerating patient access to evidence-based innovation in mental health.
- Website
Precision BioSciences57BiotechnologyDurham, USA$357.6MA clinical-stage biotechnology company developing in vivo gene editing therapies.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
Showing the 20 closest matches. See the rest on the Medincell profile.